Acrux Ltd
ASX:ACR
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.013
0.033
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| AU |
|
Acrux Ltd
ASX:ACR
|
5.7m AUD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
954.9B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
546.2B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
269.6B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
208B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
217.7B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
265.4B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.7T DKK |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
147.6B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
93.9B EUR |
Loading...
|
Market Distribution
| Min | -14 949 200% |
| 30th Percentile | -526.4% |
| Median | -25.2% |
| 70th Percentile | 6.1% |
| Max | 145 596.9% |
Other Profitability Ratios
Acrux Ltd
Glance View
Acrux Ltd. operates as a pooled development fund that invests in pharmaceutical businesses. The company is headquartered in Melbourne, Victoria. The company went IPO on 2004-09-29. The firm is engaged in developing and commercializing a portfolio of generic topical prescription pharmaceutical products which use dermal and transdermal drug delivery technology. The firm's product pipeline includes Evamist, Lenzetto, Jublia, EMLA and Testosterone Topical Solution. The firm's transdermal or topical pharmaceutical product portfolio can be segregated into approximately two streams, such as generic pharmaceutical products and specialty pharmaceutical products. The products offered by the Company are the testosterone topical solution to treat adult males who have low or no testosterone and Estradiol MDTS to treat moderate to severe hot flushes commonly associated with menopause. The company is also developing a range of topical and dermatological generic products for the United States market. The firm operates in the United States, Europe and other markets.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Acrux Ltd is -124.4%, which is below its 3-year median of -77.6%.
Over the last 3 years, Acrux Ltd’s Operating Margin has increased from -187.8% to -124.4%. During this period, it reached a low of -187.8% on Jun 30, 2022 and a high of 0.9% on Jun 30, 2023.